Tavaborole, a Novel Boron-Containing Small Molecule for the Topical Treatment of Onychomycosis, Is Noncarcinogenic in 2-Year Carcinogenicity Studies

Tavaborole, a cyclized boronic acid, has been approved by the Food and Drug Administration for the topical treatment of toenail onychomycosis. This novel, low-molecular-weight pharmaceutical compound has broad-spectrum antifungal activity against dermatophytes, yeasts, and molds responsible for the disease. Tavaborole was tested in 2-year carcinogenicity studies in mice (once daily dermal administration) and rats (once daily by oral gavage) as part of the extensive nonclinical safety program. There was no evidence of tavaborole-related neoplasms observed in either study. Based on the data gathered from these 2 carcinogenicity studies, tavaborole is considered noncarcinogenic.

Source: International Journal of Toxicology - October 9, 2014 Category: Toxicology Authors: Ciaravino, V., Coronado, D., Lanphear, C., Shaikh, I., Ruddock, W., Chanda, S. Tags: Original Articles Source Type: research